



(11) Publication number: **0 294 993 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(43) Date of publication of patent specification :
03.07.91 Bulletin 91/27

(51) Int. Cl.⁸: **A61K 9/44, A61K 9/22,
A61K 9/24, A61L 9/12**

(21) Application number: **86304974.4**

(22) Date of filing: **01.06.88**

(54) **A generic zero order controlled drug delivery system.**

(30) Priority: **11.06.87 US 61925**

(43) Date of publication of application :
14.12.88 Bulletin 88/50

(45) Publication of the grant of the patent :
03.07.91 Bulletin 91/27

(84) Designated Contracting States :
AT BE CH DE ES FR GB GR IT LI LU NL SE

(56) References cited :
**EP-A- 0 153 070
EP-A- 0 200 224
EP-A- 0 205 342
AT-B- 341 100
AT-B- 374 366**

(56) References cited :
**DE-A- 3 613 433
GB-A- 1 372 040
GB-A- 2 110 524
US-A- 2 539 036
US-A- 3 146 169
US-A- 3 851 648**

(73) Proprietor: **PFIZER INC. -
235 East 42nd Street
New York, N.Y. 10017 (US)**

(72) Inventor: **Ranade, Gautam Ramchandra
18 Wayne Drive
East Lyme Connecticut 06333 (US)**

(74) Representative: **Bradbrook, Geoffrey William
et al
PFIZER LIMITED Ramsgate Road
Sandwich Kent, CT13 9NJ (GB)**

EP 0 294 993 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Jouv , 18, rue Saint-Denis, 75001 PARIS

BEST AVAILABLE COPY